Eli Lilly and Company (NYSE:LLY) Given Average Rating of “Buy” by Brokerages

Eli Lilly and Company (NYSE:LLY) has earned an average rating of “Buy” from the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $258.22.

A number of equities research analysts have recently weighed in on LLY shares. Truist started coverage on Eli Lilly and in a research note on Tuesday, July 27th. They set a “buy” rating and a $262.00 price target on the stock. Mizuho boosted their price target on Eli Lilly and from $250.00 to $279.00 and gave the company a “buy” rating in a report on Wednesday, August 4th. Citigroup raised Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price target for the company from $210.00 to $265.00 in a report on Wednesday, September 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded Eli Lilly and from a “hold” rating to a “sell” rating and set a $244.00 target price for the company. in a research note on Monday, July 19th. Finally, Truist Securities increased their price objective on Eli Lilly and from $225.00 to $262.00 and gave the company a “buy” rating in a research note on Friday, July 2nd.

NYSE LLY opened at $237.87 on Thursday. Eli Lilly and has a 12 month low of $129.21 and a 12 month high of $275.87. The stock has a market cap of $228.12 billion, a price-to-earnings ratio of 35.45, a PEG ratio of 1.86 and a beta of 0.25. The company’s 50 day moving average is $247.65 and its two-hundred day moving average is $223.58. The company has a current ratio of 1.15, a quick ratio of 0.89 and a debt-to-equity ratio of 2.21.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Monday, August 2nd. The company reported $1.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.02). Eli Lilly and had a net margin of 22.71% and a return on equity of 119.12%. The company had revenue of $6.74 billion for the quarter, compared to analysts’ expectations of $6.59 billion. During the same period last year, the business earned $1.89 earnings per share. The company’s quarterly revenue was up 22.6% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and will post 7.87 EPS for the current year.

In other news, major shareholder Lilly Endowment Inc sold 236,542 shares of the firm’s stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $256.12, for a total transaction of $60,583,137.04. Following the completion of the sale, the insider now directly owns 108,537,712 shares of the company’s stock, valued at approximately $27,798,678,797.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 492,615 shares of company stock valued at $128,197,709. Corporate insiders own 0.13% of the company’s stock.

Several hedge funds have recently modified their holdings of LLY. Ironwood Wealth Management LLC. grew its holdings in shares of Eli Lilly and by 2.5% during the 1st quarter. Ironwood Wealth Management LLC. now owns 4,690 shares of the company’s stock worth $876,000 after purchasing an additional 114 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $350,000. Harbour Investments Inc. acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $243,000. M Holdings Securities Inc. acquired a new stake in shares of Eli Lilly and during the 1st quarter worth approximately $623,000. Finally, Harvest Fund Management Co. Ltd boosted its stake in Eli Lilly and by 64.0% in the 1st quarter. Harvest Fund Management Co. Ltd now owns 5,026 shares of the company’s stock valued at $938,000 after buying an additional 1,961 shares in the last quarter. 81.65% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

Eli Lilly & Co engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm’s products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity.

See Also: What is the QQQ ETF?

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.